This webinar provides the Medical Affairs community with a differentiated and bold view to drive the future state of Medical Affairs and what “good” looks like regarding the role of Medical Affairs in Clinical Development.
This Webinar series explores the fundamental concept of big data in Medical Affairs, from which sources can we retrieve this, what are the broader considerations when utilizing data in health and what impact this can have on our organizations, physicians, and patients, now and in the future.
In this webinar we will explore practical approaches to engaging patients in early development, introducing key resources and discussing best practices. These discussions will be tailored to meet the needs of all Medical Affairs colleagues, regardless of experience.
In this webinar, you will learn how to identify and explore additional value drivers for Medical Affairs in biopharma organizations while also building alignment towards common goals and initiating appropriate collaboration between Medical Affairs and R&D.
This podcast addresses how Medical Affairs teams should be re-evaluating their overall strategy to make sure that even in the face of uncertainty, there is a path forward for clinical design, and how Rescue sites can provide that path forward.
This podcast details the need for content curation to cut through the noise — and eventually provide patient benefit.
This podcast details ways to identify and engage diverse patients in Medical Affairs clinical trials, empowering the function’s core mission to maximize the benefit of new pharmaceutical and MedTech products to patients in the wider healthcare landscape.
Part 2 of this series will discuss statistical analysis in clinical trials including null/alternative hypotheses; statistical assumptions (type I error, significance level, type II error, statistical power); hypothesis testing; Statistics used in RCTs, including type of outcome measures, analysis of time-to-event variables (plotting and interpretation of Kaplan-Meier curves).
Early Access includes a variety of programs by which pharmaceutical companies make investigational therapies available to patients with life-threatening diseases. These patients have either exhausted available treatments or have no approved options. This presentation will review the processes and procedures to consider in the implementation of an Early Access Program and explore the opportunities and challenges posed therein.
Part 1 of this series will: define terminologies in statistics; explain different types of data (quantitative vs. qualitative); describe different ways in presenting summary data (such as proportions, means, medians, range and standard deviation); explain 95% confidence intervals; discuss bivariate analyses and appropriate statistical testing for quantitative and qualitative variables